BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil eases as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Sysco calls on Teamsters to end LA strike after economic deal reached
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $115 at Evercore ISI
August 6, 2024 5:02 AM EDTEvercore ISI analyst Cory Kasimov raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $115.00 (from $113.00) while maintaining a Outperform rating.
The analyst comments "BMRN printed an encouraging 2Q beat-and-raise w/ solid progress for Voxzogo and long-awaited strategic direction not to mention... More



